DC-CIK联合GP方案化疗对晚期NSCLC患者的疗效观察

摘要

目的:观察DC-CIK联合GP方案化疗对晚期非小细胞肺癌( non-small-cellcarcinoma,NSCLC)患者的疗效.方法:采用等距随机抽样法将90例晚期NSCLC患者分为对照组(GP方案)及观察组(DC-CIK联合GP方案),每组各45例,比较两组临床疗效.结果: 两组患者治疗总有效率分别为86. 67% 、66. 67% ,差异有统计学意义(P＜0. 05);毒副反应发生率比较,差异无统计学意义(P＞0. 05);治疗前两组T细胞亚群无明显差异,治疗后差异有统计学意义(P＜0. 05).结论: 在晚期NSCLC患者临床治疗工作中DC-CIK联合GP方案可取得理想疗效,可作为优选治疗方案推广使用.%Objective:To observe the effect of DC-CIK combined with GP chemotherapy for advanced non-small cell lung cancer (NSCLC) patients. Methods:Using isometric random sampling method,90 NSCLC patients were divided into control group (GP) and observation group (DC-CIK combined with GP),each group had 45 cases. The clinical efficacy of the two groups were compared. Re-sults:The total efficiency of the two groups were 86. 67% and 66. 67% ,the difference was statistically significant (P＜0. 05). There was no statistically significant difference adverse reaction rate in the between groups (P＞0. 05). There was no significant difference between the two groups of T cell subsets before treatment,the difference was statistically significant after treatment (P＜0. 05). Con-clusion:The clinical treatment of DC-CIK combined with GP scheme in patients with advanced NSCLC can achieve the desired effect, and can be used as the preferred treatment to promote the use of program.